PAZEO

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: c24f577aea36a4b6
Drug Approval Canada Name: PAZEO
Product Name: PAZEO
Status: Marketed
Status Date: 2018-03-12
Original Market Date: 2018-03-12
Din: 02458551
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Ophthalmic
Schedule: Prescription
Ahfs: 52:02.00
Atc Original: S01GX09 OLOPATADINE
Atc Name: s 01 gx 09
Aig Number: 0132394004
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

OLOPATADINE (OLOPATADINE HYDROCHLORIDE)

0.7 % / W/V

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

c24f577aea36a4b6

Type

Standard